Percutaneous CT-guided biopsy of lytic bone lesions in patients clinically suspected of lung cancer: diagnostic performances for pathological diagnosis and molecular testing

The management of advanced stage non-small cell lung cancer (NSCLC) has significantly improved in the last decades with the introduction of personalized treatments showing better efficacy than chemotherapy [1,2]. However, such treatments require precise histopathological subtyping of the tumor, molecular testing and PD-L1 (Programmed death-ligand 1) immunohistochemistry (IHC) to predict immune checkpoint inhibitor response. In cases of tumor progression, a rebiopsy is often performed with specific molecular testing to detect mechanisms of EGFR (epidermal growth factor receptor) or ALK (anaplastic lymphoma kinase) inhibitor resistance.

Source: Lung Cancer - December 18, 2019 Category: Cancer & Oncology Authors: Anne-Claire Toffart, St éphane Asfari, Anne Mc Leer, Emilie Reymond, Adrien Jankowski, Denis Moro-Sibilot, Olivier Stephanov, Julien Ghelfi, Sylvie Lantuejoul, Gilbert R. Ferretti Source Type: research